eligibility_summary
Eligibility: CLDN6-positive platinum-resistant/refractory ovarian, or advanced testicular or endometrial cancer, measurable disease (RECIST 1.1), ECOG 0–2, adequate organ function. Excludes: CNS metastases, leptomeningeal disease, or spinal cord compression, uncontrolled active infection or other prohibitive condition, prior CLDN6-targeted therapy, concurrent enrollment in another investigational trial.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drug/intervention: CTIM-76, a humanized T-cell–engaging bispecific antibody (immunotherapy) directed at Claudin-6 (CLDN6). Mechanism: one arm binds CLDN6 on tumor cells while the other engages T cells, driving immune synapse formation, T-cell activation, and cytotoxic killing of CLDN6-positive cells, administered weekly with a priming dose in expansion. Cells/pathways targeted: CLDN6-expressing solid tumor cells (notably platinum-resistant/refractory ovarian, plus testicular and endometrial cancers) and adaptive immune effector T cells via T-cell activation signaling.